# Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

> **NCT01254136** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** INCB007839 300mg BID
- **DRUG:** Trastuzumab
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01254136
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Incyte has suspended development of the compound.
- **Last updated:** 2012-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254136, "Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01254136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*